Royalty Pharma plc
For the period ended Dec 31, 2024. Filed Feb 12, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 12, 2025
RPRX$69.45+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, 202 and
(In thousands, except par value)
| As of December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $929,026 | $477,010 |
| Financial royalty assets | 783,770 | 738,438 |
| Available for sale debt securities | 58,200 | 18,300 |
| Other royalty income receivable | 26,956 | 22,405 |
| Other current assets | 4,187 | 18,040 |
| Total current assets | 1,802,139 | 1,274,193 |
| Financial royalty assets, net | 15,127,158 | 14,088,655 |
| Equity securities | 186,960 | 199,487 |
| Available for sale debt securities | 693,500 | 437,100 |
| Equity method investments | 379,424 | 375,894 |
| Other assets | 33,534 | 6,522 |
| Total assets | $18,222,715 | $16,381,851 |
| Liabilities and shareholders’ equity | ||
| Current liabilities | ||
| Distributions payable to legacy non-controlling interests | $75,811 | $83,155 |
| Accounts payable and accrued expenses | 13,370 | 15,165 |
| Interest payable | 98,062 | 51,682 |
| Current portion of long-term debt | 997,773 | — |
| Other current liabilities | 68,600 | 11,375 |
| Total current liabilities | 1,253,616 | 161,377 |
| Long-term debt | 6,614,653 | 6,135,285 |
| Other liabilities | 12,080 | 900 |
| Total liabilities | 7,880,349 | 6,297,562 |
| Commitments and contingencies | ||
| Shareholders’ equity | ||
| Class A ordinary shares, $0.0001 par value; issued and outstanding: 2024–445,985 and 2023–446,692 | 45 | 45 |
| Class B ordinary shares, $0.000001 par value; issued and outstanding: 2024–143,128 and 2023–150,743 | — | — |
| Class R redeemable shares, £1 par value; issued and outstanding: 2024–50 and 2023–50 | 63 | 63 |
| Deferred shares, $0.000001 par value; issued and outstanding: 2024–392,255 and 2023–384,640 | — | — |
| Additional paid-in capital | 4,103,482 | 4,011,435 |
| Retained earnings | 2,845,653 | 2,517,583 |
| Non-controlling interests | 3,395,785 | 3,557,792 |
| Treasury interests | (2,662) | (2,629) |
| Total shareholders’ equity | 10,342,366 | 10,084,289 |
| Total liabilities and shareholders’ equity | $18,222,715 | $16,381,851 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.